Retrospective autoevaluation of the results of intrinsic brain tumor surgeries – consecutive cohort of 270 surgeries within one neurosurgical center of the NOS ČOS (Neurooncological section of the Czech Oncology Society) from 2015–2017

Česká verzia

Authors: R. Bartoš ^1,2; D. Ospalík ³; A. Malucelli ¹; P. Vachata ¹; M. Sameš ¹; T. Kazda ^4,5; D. Šmejkalová-Musilová ⁶; F. Třebický ⁷
Authors place of work: Neurochirurgická klinika UJEP, a Masarykova nemocnice, KZ a. s., Ústí, nad Labem ¹; Anatomický ústav, 1. LF UK, Praha ²; Neurologické oddělení, Masarykova, nemocnice, KZ a. s., Ústí nad Labem ³; Klinika radiační onkologie Masarykova, onkologického ústavu, Brno ⁴; Klinika radiační onkologie LF MU, Brno ⁵; Onkologické oddělení, Komplexní, onkologické centrum, Masarykova, nemocnice, KZ a. s., Ústí nad Labem ⁶; Ústav radiační onkologie, Nemocnice, na Bulovce, Praha ⁷
Published in the journal: Cesk Slov Neurol N 2019; 82(4): 401-409
Category: Original Paper
doi: https://doi.org/10.14735/amcsnn2019401

Summary

Aim: Retrospective evaluation of a consecutive cohort of adult intrinsic brain tumor patients operated in Ústí nad Labem (Czech Republic) from 2015 to 2017 focusing on the assessment of postoperative morbidity.

Patients and Methods: Basic evaluated variables included neurological morbidity, subgaleal cerebrospinal fluid collection or duration of hospitalization. In the subgroup of patients with high-grade gliomas, the parameters of the organization of subsequent oncological care, such as the waiting time until the start of radiotherapy were evaluated, together with overall survival estimations.

Results: A total of 270 surgeries were performed (average age 60 years, 59% men). Newly diagnosed glioblastomas (GBM) represented 37.4% of the surgeries, while metastases were 32.6% of the total. Severe neurological morbidity was observed in 18 patients (6.7%). Subgaleal cerebrospinal fluid collection was diagnosed in 13% of patients. The average length of hospitalization was 6.6 days. About 30% of patients underwent complete oncological treatment. The median waiting time for radiotherapy was 46 days after surgery (no effect on overall survival). The median overall survival of patients with GBM was 8.8 months (95% CI 2.2–13.4). Significantly longer overall survival was observed in patients who were able to undergo treatment according to the Stupp regimen (22.6 vs. 4.3 months, P < 0.001), those after resection vs. biopsy (12.4 vs. 4 months, P < 0.001) and younger patients ≤ 60 years (19.4 vs. 5.1 months, P < 0.001).

Conclusion: We observed overall low postoperative morbidity in our cohort of neurooncology patients. Self-evaluation of results is an integral part of complex neurosurgical care.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

内在性脑肿瘤手术结果的回顾性自动评估– 2015年至2017年，在NOSČOS（捷克肿瘤学会神经病学分会）的一个神经外科中心内连续进行270例手术

目的：回顾性评估2015年至2017年在Ústí nad Labem（捷克共和国）进行的成年内在脑肿瘤患者的队列研究，重点是评估术后发病率。

患者和方法：评估的基本变量包括神经疾病发病率、枕下脑脊液收集或住院时间。在高级别胶质瘤患者的亚组中，评估了后续肿瘤护理的组织参数，如放疗开始前的等待时间，以及总体生存评估。

结果：总共进行了270例手术（平均年龄60岁，男性占59％）。新诊断的胶质母细胞瘤（GBM）占手术的37.4％，而转移灶占总数的32.6％。 18例患者（6.7％）出现严重的神经系统疾病。13%的患者被诊断为心下脑脊液收集。平均住院时间为6.6天。大约30%的病人接受了完全的肿瘤治疗。放疗的平均等待时间为术后46天(对总生存率无影响)。GBM患者的中位总生存期为8.8个月(95% CI 2.2-13.4)。能够按照Stupp方案进行治疗的患者的总生存期明显延长(22.6个月vs. 4.3个月，P < 0.001);手术切除与活检(12.4 vs. 4个月，P < 0.001)及≤60岁的年轻患者(19.4 vs. 5.1个月，P < 0.001)。

结论：我们在神经肿瘤患者队列中观察到总体的术后发病率较低。结果的自我评估是复杂的神经外科护理不可或缺的一部分。
关键词：神经肿瘤–脑肿瘤–放射治疗

Keywords:

radiotherapy – neurooncology – brain tumor

Zdroje

1. Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131(6): 803–820. doi: 10.1007/ s00401-016-1545-1.

2. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol 2014; 16(1): 113–122. doi: 10.1093/ neuonc/ not137.

3. Grabowski MM, Recinos PF, Nowacki AS et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 2014; 121(5): 1115–1123. doi: 10.3171/ 2014.7.JNS132449.

4. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95(2): 190–198.

5. McGirt MJ, Mukherjee D, Chaichana KL et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 2009; 65(3): 463–470. doi: 10.1227/ 01.NEU.0000349763.42238.E9.

6. Berghoff AS, Brastianos PK. Toward precision medicine in brain metastases. Semin Neurol 2018; 38(1): 95–103. doi: 10.1055/ s-0038-1627469.

7. Bartoš R, Třebický F, Malucelli A et. al. Volumetrické vyhodnocení efektu následné onkologické léčby (radioterapie a chemoterapie) při inoperabilní progresi či významném reziduu nízkostupňového gliomu. Cesk Slov Neurol N 2014; 77/ 110(2): 216–222.

8. Brock S, Saleh C, Zekaj E et al. How to compare clinical results of different neurosurgical centers? Is a classification of complications in neurosurgery necessary for this purpose? Surg Neurol Int 2016; 7 (Suppl 20): S565–S569. doi: 10.4103/ 2152-7806.188471.

9. Broggi M, Zattra C, Ferroli P. How to compare outcomes and complications in neurosurgery: We must make the mission possible! Surg Neurol Int 2018; 9: 65. doi: 10.4103/ sni.sni_424_17.

10. Bartoš R, Němcová V, Radovnický T et al. Gliomy limbického a paralimbického systému, technika a výsledky resekcí. Cesk Slov Neurol N 2016; 79/ 112(2): 131–147. doi: 10.14735/ amcsnn2016131.

11. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5): 459–466. doi: 10.1016/ S1470-2045(09)70025-7.

12. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987–996. doi: 10.1056/ NEJMoa043330.

13. Dasenbrock HH, Liu KX, Devine CA et al. Length of hospital stay after craniotomy for tumor: a National Surgical Quality Improvement Program analysis Dasenbrock. Neurosurg Focus 2015; 39(6): E12. doi: 10.3171/ 2015.10.FOCUS15386.

14. Trinh VT, Davies JM, Berger MS. Surgery for primary supratentorial brain tumors in the United States, 2000–2009: effect of provider and hospital caseload on complication rates. J Neurosurg 2015; 122(2): 280–296. doi: 10.3171/ 2014.9.JNS131648.

15. Senders JT, Muskens IS, Cote DJ et al. Thirty-day outcomes after craniotomy for primary malignant brain tumors: a National Surgical Quality Improvement Program analysis. Neurosurgery 2018; 83(6): 1249–1259. doi: 10.1093/ neuros/ nyy001.

16. Mahajan A, Ahmed S, McAleer MF et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18(8): 1040–1048. doi: 10.1016/ S1470-2045(17)30414-X.

17. Brown PD, Ballman KV, Cerhan JH et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/ CEC•3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18(8): 1049–1060. doi: 10.1016/ S1470-2045(17)30441-2.

18. Amayiri N, Swaidan M, Abuirmeileh N et al. Video-teleconferencing in pediatric neuro-oncology: ten years of experience. J Glob Oncol 2018; 4: 1–7. doi: 10.1200/ JGO.2016.008276.

19. Qaddoumi I, Mansour A, Musharbash A et al. Impact of telemedicine on pediatric neuro-oncology in a developing country: the Jordanian-Canadian experience. Pediatr Blood Cancer 2007; 48(1): 39–43. doi: 10.1002/ pbc.21085.

20. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/ IV gliomas. Radiother Oncol 2000; 57(2): 131–136.

21. Irwin C, Hunn M, Purdie G et al. Delay in radiotherapy shortens survival in patients with high grade glioma. J Neurooncol 2007; 85(3): 339–343. doi: 10.1007/ s11060-007-9426-z.

22. Blumenthal DT, Won M, Mehta MP et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol 2009; 27(5): 733–739. doi: 10.1200/ JCO.2008.18.9035.

23. Sun MZ, Oh T, Ivan ME et al. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg 2015; 122(5): 1144–1150. doi: 10.3171/ 2014.9.JNS14193.

24. Louvel G, Metellus P, Noel G et al. Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients. Radiother Oncol 2016; 118(1): 9–15. doi: 10.1016/ j.radonc.2016.01.001.

25. Hannan EL, Racz MJ, Walford G et al. Predictors of readmission for complications of coronary artery bypass graft surgery. JAMA 2003; 290(6): 773–780. doi: 10.1001/ jama.290.6.773.

26. Hannan EL, Zhong Y, Lahey SJ et al. 30-day readmissions after coronary artery bypass graft surgery in New York state. JACC Cardiovasc Interv 2011; 4(5): 569–576. doi: 10.1016/ j.jcin.2011.01.010.

27. Hendren S, Morris AM, Zhang W et al. Early discharge and hospital readmission after colectomy for cancer. Dis Colon Rectum 2011; 54(11): 1362–1367. doi: 10.1097/ DCR.0b013e31822b72d3.

28. Dasenbrock HH, Yan SC, Smith TR et al. Readmission after craniotomy for tumor: a national surgical quality improvement program analysis. Neurosurgery 2017; 80(4): 551–562. doi: 10.1093/ neuros/
nyw062.

29. Stupp R, Taillibert S, Kanner A et al. Treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318(23): 2306–2316. doi: 10.1001/ jama.2017.
18718.